Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Chemotherapy-induced nausea and vomiting (CINV) are common side effects, classified according to timing and severity. Conventional agents such as dexamethasone are effective but have various side effects. For moderately emetogenic chemotherapy, dexamethasone-sparing antiemetic therapies have been developed to minimize these side effects. This systematic review evaluated the efficacy and safety of dexamethasone-sparing antiemetic therapy for highly emetogenic chemotherapy (HEC).
Methods: We performed a thorough literature search for studies related to dexamethasone-sparing antiemetic therapy with neurokinin-1 antagonists (NKRA) for HEC using the PubMed, Cochrane Library, and Ichushi-Web databases. A qualitative analysis of the combined data was performed and risk differences with confidence intervals were calculated.
Results: Two reviewers independently assessed the 425 records and 12 full-text articles were evaluated for eligibility. Two studies were included in the qualitative and meta-analyses. These studies included anthracycline-cyclophosphamide (AC) regimens and cisplatin-based regimens, with palonosetron as the serotonin receptor antagonist. In the two studies, no difference was found in the prevention of vomiting (delayed complete response). However, non-inferiority was not demonstrated in the subgroup that received cisplatin-containing regimens. Delayed complete control showed different results for nausea prevention; however, there was no significant difference in the meta-analysis. Only one report has shown non-inferiority for delayed total control. Although the strength of evidence for individual outcomes varied, there was no difference in the duration of dexamethasone administration.
Conclusions: This systematic review and meta-analysis revealed that dexamethasone-sparing antiemetic therapy with NKRA and palonosetron can be used to prevent CINV in HEC, limited to AC combination therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10147-024-02624-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Going beyond the 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting.
Eur J Cancer
June 2025
Medical Oncology, Genolier Cancer Center, Genolier, Switzerland.
The MASCC/ESMO guidelines for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting were updated in 2023 by a Consensus Committee of 34 multidisciplinary international healthcare professionals and three patient advocates. Guideline-recommended prophylactic anti-emetic strategies can control chemotherapy-induced nausea and vomiting (CINV) in many patients, but unaddressed issues remain. Across a series of meetings, we evaluated these guidelines to identify possible evidence gaps which warrant further exploration.
View Article and Find Full Text PDFA prospective analysis of efficacy of dexamethasone-sparing antiemetic regimens in high and moderate emetogenic chemotherapy.
J Oncol Pharm Pract
March 2025
Department of Pharmacy Practice, KMCH College of Pharmacy, Coimbatore, India.
ObjectivesMultiple moderate-to-severe side effects associated with dexamethasone (DEX) were observed by patients undergoing a multi-day DEX regimen for delayed chemotherapy-induced nausea and vomiting (CINV). Therefore, there is increasing demand in clinical practice to lower DEX doses in subsequent emetogenic treatment cycles. This study aimed to evaluate the efficacy of the DEX-sparing antiemetic regimens in high- and moderate- emetogenic chemotherapy (HEC, MEC respectively) and to explore its functional impact on health-related Quality of Life (QoL).
View Article and Find Full Text PDFDexamethasone-Sparing Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting in Highly and Moderately Emetogenic Chemotherapy: The SHEILD Study.
Cureus
September 2024
Medical Affairs, Zydus Lifesciences Ltd., Ahmedabad, IND.
Article Synopsis
- The study examines the effectiveness of a combination treatment of Generic Netupitant and Palonosetron (Nykron) with dexamethasone in preventing chemotherapy-induced nausea and vomiting (CINV) in patients undergoing highly and moderately emetogenic chemotherapy.
- It assesses outcomes like complete response and complete control of nausea/vomiting during both the acute (0-24 hours) and delayed (24-120 hours) phases after chemotherapy, gathering data from 372 cancer patients primarily diagnosed with breast or gastrointestinal cancers.
- Results indicate a high success rate for the regimen, with an overall response of 96.9%, suggesting it is an effective option for managing CINV while potentially reducing the need for higher
Multi-day vs single-day dexamethasone for the prophylaxis of chemotherapy-induced nausea and vomiting: systematic review and meta-analysis.
Support Care Cancer
October 2024
Genolier Cancer Center, Genolier, Switzerland.
Introduction: Over the past decade, several randomized controlled trials have compared single-day dexamethasone (dexamethasone-sparing) regimens to the current standard multi-day dexamethasone antiemetic regimen for chemotherapy-induced nausea and vomiting (CINV). The aim of this systematic review and meta-analysis is to compare the efficacy and safety of dexamethasone-sparing regimens to standard multi-day dexamethasone, used for the prophylaxis of CINV.
Methods: Ovid Medline and Embase were searched from database inception to March 2024.
Efficacy and safety of dexamethasone sparing for the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy: a systematic review and meta-analysis of Clinical Practice Guidelines for Antiemesis 2023 from Japan Society of Clinical Oncology.
Int J Clin Oncol
December 2024
Department of Obstetrics and Gynecology, Hamamatsu University School of Medicine, 1‑20‑1 Handayama, Chuo-Ku, Hamamatsu, Shizuoka, 431‑3192, Japan.
Article Synopsis
- Palonosetron is a second-generation anti-nausea drug that might be more effective than first-generation medications, and this study explores how dexamethasone (DEX) works with it during chemotherapy.
- Researchers compared the effects of giving DEX for 1 day versus 3 days in preventing nausea and vomiting after moderately emetogenic chemotherapy (MEC), using data from studies published between 1990 and 2020.
- The findings showed that while the 3-day DEX group had a higher rate of no vomiting, there were no major differences in most anti-nausea effects, suggesting that DEX treatment could be shortened to just 1 day when paired with palonosetron.